CEBPA and acute myeloid leukemia: Additionally, cytogenetic testing further identified the presence of NUP98-NSD1 fusion, Fms-like tyrosine kinase 3 (FLT3) mutation, and CCAAT-enhancer binding protein alpha (CEBPA) mutation, indicating AML-M1 type with high-risk cytogenetics.